What is B. Riley’s Forecast for Veru Q1 Earnings?

Veru Inc. (NASDAQ:VERU) – B. Riley issued their Q1 2025 earnings per share estimates for Veru in a research note issued to investors on Thursday, January 9th. B. Riley analyst W. Wood anticipates that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Veru’s current full-year earnings is ($0.30) per share. B. Riley also issued estimates for Veru’s Q2 2025 earnings at ($0.05) EPS.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.

Several other research firms also recently weighed in on VERU. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Veru in a research note on Thursday, January 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Veru in a report on Tuesday, November 5th.

Veru Trading Up 7.7 %

NASDAQ:VERU opened at $0.78 on Monday. Veru has a twelve month low of $0.36 and a twelve month high of $1.92. The company has a market cap of $114.44 million, a PE ratio of -1.63 and a beta of -0.53. The company’s 50 day moving average is $0.69 and its two-hundred day moving average is $0.80.

Institutional Trading of Veru

A number of hedge funds have recently added to or reduced their stakes in VERU. Perceptive Advisors LLC raised its position in shares of Veru by 26.5% in the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock worth $5,942,000 after acquiring an additional 1,478,578 shares during the period. State Street Corp raised its holdings in Veru by 4.3% in the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company’s stock worth $1,593,000 after purchasing an additional 84,483 shares during the period. Geode Capital Management LLC raised its holdings in Veru by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company’s stock worth $2,261,000 after purchasing an additional 131,720 shares during the period. Barclays PLC boosted its position in Veru by 309.2% during the third quarter. Barclays PLC now owns 184,777 shares of the company’s stock worth $142,000 after purchasing an additional 139,617 shares in the last quarter. Finally, Choreo LLC grew its holdings in Veru by 261.3% in the second quarter. Choreo LLC now owns 332,050 shares of the company’s stock valued at $292,000 after purchasing an additional 240,134 shares during the period. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.